Xencor (XNCR) Liabilities and Shareholders Equity (2013 - 2026)
Xencor (XNCR) reported Liabilities and Shareholders Equity of $736.8 million for Q1 2026, down 18.55% year-over-year from $904.7 million in Q1 2025, and down 15.84% quarter-over-quarter from $875.5 million in Q4 2025.
Xencor (XNCR) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $736.8 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $736.8 million, down 18.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 9.1% YoY), and the FY2025 annual result was $875.5 million, down 8.03% from the prior year.
- Liabilities and Shareholders Equity fell to $736.8 million in Q1 2026 per XNCR's latest filing, from $875.5 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $999.9 million in Q3 2024 and troughed at $736.8 million in Q1 2026.
- A 5-year average of $863.0 million and a median of $857.9 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity gained 28.45% in 2024, then slipped 18.55% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $846.3 million in 2022, then climbed by 14.05% to $965.1 million in 2023, then declined by 1.37% to $951.9 million in 2024, then decreased by 8.03% to $875.5 million in 2025, then slipped by 15.84% to $736.8 million in 2026.
- Business Quant data shows XNCR's Liabilities and Shareholders Equity at $736.8 million in Q1 2026, $875.5 million in Q4 2025, and $868.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 736.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 736.85 Mn |
| Dec 31, 2025 | 875.50 Mn |
| Sep 30, 2025 | 868.81 Mn |
| Jun 30, 2025 | 879.42 Mn |
| Mar 31, 2025 | 904.69 Mn |
| Dec 31, 2024 | 951.95 Mn |
| Sep 30, 2024 | 999.90 Mn |
| Jun 30, 2024 | 840.62 Mn |
| Mar 31, 2024 | 896.85 Mn |
| Dec 31, 2023 | 965.14 Mn |
| Sep 30, 2023 | 778.43 Mn |
| Jun 30, 2023 | 778.12 Mn |
| Mar 31, 2023 | 803.41 Mn |
| Dec 31, 2022 | 846.27 Mn |
| Sep 30, 2022 | 835.27 Mn |
| Jun 30, 2022 | 851.33 Mn |
| Mar 31, 2022 | 857.92 Mn |
| Dec 31, 2021 | 838.21 Mn |
| Sep 30, 2021 | 697.26 Mn |
| Jun 30, 2021 | 695.60 Mn |